BPD
MCID: BRN056
MIFTS: 57

Bronchopulmonary Dysplasia (BPD)

Categories: Fetal diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 19 58 75 53 5 36 63 71
Bpd 19 58

Characteristics:


Prevelance:

1-5/10000 (Europe) 58

Age Of Onset:

Infancy,Neonatal 58

Classifications:

Orphanet: 58  
Rare respiratory diseases
Developmental anomalies during embryogenesis


External Ids:

MESH via Orphanet 44 D001997
ICD10 via Orphanet 32 P27.1
UMLS via Orphanet 72 C0006287
Orphanet 58 ORPHA70589
UMLS 71 C0006287

Summaries for Bronchopulmonary Dysplasia

PubMed Health : 63 Bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube). Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD. Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary: Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and newborn respiratory distress syndrome. An important gene associated with Bronchopulmonary Dysplasia is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Innate Immune System and NF-KappaB Family Pathway. The drugs Beractant and Zinc cation have been mentioned in the context of this disorder. Affiliated tissues include Lung, and related phenotypes are emphysema and cough

GARD: 19 Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.

Orphanet: 58 Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.

Wikipedia: 75 Bronchopulmonary dysplasia (BPD; part of the spectrum of chronic lung disease of infancy) is a chronic... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.3 SCGB1A1 RNASE3 ELANE CXCL8
2 newborn respiratory distress syndrome 31.3 SFTPB CXCL8
3 chorioamnionitis 30.8 IL1RN FLT1 ELANE CXCL8
4 adult respiratory distress syndrome 30.7 SFTPB SELL SCGB1A1 IL1RN FGF7 ELANE
5 vascular disease 30.7 TIMP1 SOD1 RBP4 ELANE
6 pneumonia 30.6 SFTPB SCGB1A1 ELANE CXCL8
7 gastroesophageal reflux 30.5 IL1RN ELANE CXCL8
8 pulmonary edema 30.5 SCGB1A1 IL1RN FGF7 CXCL8
9 pulmonary fibrosis 30.4 TIMP1 FGF7 ELANE CXCL8
10 pre-eclampsia 30.4 SOD1 SELL FLT1 CXCL8
11 respiratory failure 30.4 SOD1 SFTPB SCGB1A1 RNASE3 FGF7 ELANE
12 extrinsic allergic alveolitis 30.2 SELL ELANE CXCL8
13 meconium aspiration syndrome 30.2 SFTPB SCGB1A1 CXCL8
14 bronchitis 30.2 RNASE3 ELANE CXCL8
15 interstitial lung disease 30.2 TIMP1 SFTPB IL1RN CXCL8
16 bronchiolitis obliterans 30.2 TIMP1 SCGB1A1 CXCL8
17 neonatal respiratory failure 30.2 SFTPB SCGB1A1 FGF10
18 pulmonary hemosiderosis 30.2 SFTPB IL1RN
19 allergic asthma 30.2 SCGB1A1 RNASE3 CXCL8
20 diaphragmatic hernia, congenital 30.1 SFTPB FGF7 FGF10
21 hypertension, essential 30.1 TXN TIMP1 SOD1 RBP4 FLT1 CXCL8
22 rhinitis 29.9 SCGB1A1 RNASE3 CXCL8
23 pulmonary disease, chronic obstructive 29.9 TIMP1 SFTPB SCGB1A1 RNASE3 ELANE CXCL8
24 exercise-induced bronchoconstriction 29.8 SCGB1A1 RNASE3 CXCL8
25 gastroenteritis 29.8 RNASE3 IL1RN CXCL8
26 bronchopneumonia 29.7 ELANE CXCL8
27 pulmonary emphysema 29.7 TIMP1 FGF7 ELANE CXCL8
28 otitis media 29.7 RNASE3 ELANE CXCL8
29 proteasome-associated autoinflammatory syndrome 1 29.6 SELL RNASE3 IL1RN ELANE CXCL8
30 asthma 29.6 TIMP1 SFTPB SELL SCGB1A1 RNASE3 ELANE
31 allergic rhinitis 29.6 SCGB1A1 RNASE3 CXCL8
32 lung disease 29.4 TXN TIMP1 SOD1 SFTPB SCGB1A1 RNASE3
33 cataract 29.2 TXN TIMP1 SOD1 IL1RN CXCL8
34 cystic fibrosis 28.8 TXN TIMP1 SFTPB RNASE3 RBP4 IL1RN
35 heart disease 28.7 SOD1 RBP4 IL1RN FLT1 ELANE CXCL8
36 interstitial lung disease 2 28.6 TIMP1 SFTPB SCGB1A1 IL1RN FGF7 FGF10
37 borderline personality disorder 11.4
38 pulmonary hypertension, neonatal 11.1
39 pulmonary hypertension 11.0
40 patent ductus arteriosus 1 10.9
41 personality disorder 10.8
42 respiratory distress syndrome in premature infants 10.8
43 exudative vitreoretinopathy 1 10.8
44 keratomalacia 10.8
45 enterocolitis 10.7
46 cerebral palsy 10.7
47 perinatal necrotizing enterocolitis 10.7
48 respiratory syncytial virus infectious disease 10.6
49 periventricular leukomalacia 10.6
50 cone-rod dystrophy 2 10.5

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

58 30 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emphysema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002097
2 cough 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012735
3 premature birth 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001622
4 respiratory distress 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002098
5 small for gestational age 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001518
6 chronic lung disease 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006528
7 respiratory failure requiring assisted ventilation 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004887
8 hyperoxemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012419
9 sleep disturbance 58 30 Frequent (33%) Frequent (79-30%)
HP:0002360
10 diaphragmatic paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0006597
11 central apnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002871
12 exercise intolerance 58 30 Frequent (33%) Frequent (79-30%)
HP:0003546
13 right ventricular hypertrophy 58 30 Frequent (33%) Frequent (79-30%)
HP:0001667
14 right ventricular failure 58 30 Frequent (33%) Frequent (79-30%)
HP:0001708
15 wheezing 58 30 Frequent (33%) Frequent (79-30%)
HP:0030828
16 atelectasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100750
17 tracheobronchomalacia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002786
18 pulmonary sequestration 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100632
19 dyspnea 58 Very frequent (99-80%)
20 abnormal lung morphology 58 Very frequent (99-80%)
21 abnormal respiratory system morphology 58 Frequent (79-30%)
22 functional respiratory abnormality 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ELANE FGF10 FGF7 FLT1 IL1RN RBP4
2 immune system MP:0005387 9.85 ELANE FGF10 FGF7 FLT1 IL1RN RBP4
3 reproductive system MP:0005389 9.56 FGF10 FGF7 FLT1 IL1RN RBP4 SELL
4 hematopoietic system MP:0005397 9.32 ELANE FGF10 FGF7 FLT1 IL1RN RBP4

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMed Health treatment related to Bronchopulmonary Dysplasia: 63

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine. The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs . It helps keep the lungs open so your infant can breathe in air once he or she is born. Corticosteroids also can help your baby's lungs , brain , and kidneys develop more quickly while he or she is in the womb . Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function. These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Beractant Approved Phase 4 108778-82-1
2
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
3
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
4
Salbutamol Approved, Vet_approved Phase 4 18559-94-9 2083
5
Procaterol Approved, Investigational Phase 4 72332-33-3 688561 4916
6
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
7
Azithromycin Approved Phase 4 83905-01-5 447043
8
Caffeine Approved Phase 4 58-08-2 2519
9
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
10
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
11 Dermatologic Agents Phase 4
12 Bronchodilator Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Hormones Phase 4
15 Pulmonary Surfactants Phase 4
16 Hormone Antagonists Phase 4
17 glucocorticoids Phase 4
18 Respiratory System Agents Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Neurotransmitter Agents Phase 4
21 Anti-Bacterial Agents Phase 4
22 Anti-Infective Agents Phase 4
23 Phosphodiesterase Inhibitors Phase 4
24 Central Nervous System Stimulants Phase 4
25 Citrate Phase 4
26 Caffeine citrate Phase 4
27
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
28
Tocopherol Approved, Investigational Phase 3 1406-66-2
29
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
30
Chlorothiazide Approved, Vet_approved Phase 2, Phase 3 58-94-6 2720
31
Calfactant Approved Phase 3 183325-78-2
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
34
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
35
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
36
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
37
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
38 Poractant alfa Approved Phase 3 129069-19-8
39
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
40
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
41
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
42
Ethanol Approved Phase 3 64-17-5 702
43
Benzyl alcohol Approved Phase 3 100-51-6 244
44
Clarithromycin Approved Phase 3 81103-11-9 84029
45
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
46
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
47
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
50
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 3 59-02-9, 10191-41-0 2116 14985

Interventional clinical trials:

(show top 50) (show all 264)
# Name Status NCT ID Phase Drugs
1 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Unknown status NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
2 Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study Unknown status NCT03275415 Phase 4 budesonide;Saline
3 Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure Unknown status NCT02140580 Phase 4
4 Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant Unknown status NCT04050488 Phase 4 Zinc Sulfate;Placebos
5 Early Administration of Surfactant in Spontaneous Breathing (TAKE CARE) Versus InSurE (Intubation, Surfactant, Extubation) : A Pilot Study Unknown status NCT01329432 Phase 4
6 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
7 Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia Completed NCT02447250 Phase 4 Varied albuterol dose response
8 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
9 Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia Completed NCT01039285 Phase 4 Curosurf
10 Randomized Clinical Trial: Use of Azithromycin to Prevent Lung Damage in Preterm Newborns Under Mechanical Ventilation Completed NCT03485703 Phase 4 Azithromycin;Placebo
11 The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant Recruiting NCT05311228 Phase 4 Azithromycin Powder
12 Intra-tracheal Instillation of Budesonide Along With Surfactant in Preterm Infants to Prevent Chronic Lung Disease Recruiting NCT05364385 Phase 4 Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL);Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
13 The Caffeine Therapy in the Fetal to Neonatal Transition in Preterms Recruiting NCT05454332 Phase 4 Early Caffeine administration
14 A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates Active, not recruiting NCT03086473 Phase 4 Caffeine Citrate;Placebo (Normal Saline)
15 Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide Withdrawn NCT02853253 Phase 4
16 Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
17 Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants Unknown status NCT03876704 Phase 3 High dose of fat-Soluble Vitamin;Conventional dose of fat-Soluble Vitamin
18 Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
19 Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease Unknown status NCT01721655 Phase 2, Phase 3 Spironolactone;Placebo
20 Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants Completed NCT00433212 Phase 3
21 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide Completed NCT01022580 Phase 3 Infasurf surfactant (ONY, Inc.);Sham (No Treatment)
22 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3 Budesonide
23 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3 dexamethasone;methylprednisolone
24 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth Completed NCT00931632 Phase 3 Inhaled Nitric Oxide;Placebo
25 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia in Preterm Infants Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
26 Inhaled NO for the Prevention of Chronic Lung Disease Completed NCT00006401 Phase 3 iNO
27 A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation Completed NCT01006629 Phase 2, Phase 3
28 Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD) Completed NCT00011362 Phase 3 Dexamethasone Early;Dexamethasone Late
29 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
30 A Randomized, Controlled Trial of Synchronized Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Using the Infant Flow Advance to Facilitate Successful Extubation in Premature Infants. Completed NCT00188968 Phase 3
31 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
32 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
33 Randomized Comparison of Two Models of Post-NICU Care for Preterm Infants With Neonatal Chronic Lung Disease Completed NCT00314431 Phase 3
34 Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants Completed NCT00233324 Phase 3 Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
35 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3 beclomethasone
36 Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial Completed NCT01600430 Phase 2, Phase 3
37 Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial Completed NCT00623740 Phase 3 hydrocortisone;placebo
38 Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
39 Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: a Placebo-controlled Randomized Multicenter Trial Recruiting NCT04440670 Phase 3
40 Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants ("The Budesonide in Babies (BiB) Trial") Recruiting NCT04545866 Phase 3 budesonide (Pulmicort nebulizing suspension).;surfactant (poractant alfa;Curosurf)
41 Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial) Active, not recruiting NCT02371460 Phase 3
42 A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age Active, not recruiting NCT01353313 Phase 3 Hydrocortisone;Placebo
43 Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy? Active, not recruiting NCT01702805 Phase 3
44 Inhaled Nitric Oxide and Neuroprotection in Premature Infants Active, not recruiting NCT00515281 Phase 2, Phase 3 inhaled nitric oxide;oxygen
45 A Randomized Controlled Trial of Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome Active, not recruiting NCT03231735 Phase 2, Phase 3
46 Efficacy and Safety of the Intratracheal Administration of Budesonide With Porcine Pulmonary Surfactant in Very Preterm Infants to Prevent Bronchopulmonary Dysplasia: Randomized Clinical Trial (BuS Trial) Not yet recruiting NCT04862377 Phase 3 Poractant Alfa Intratracheal Suspension [Curosurf];Budesonide 0.5 MG/ML
47 Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: a Non-Randomized Case-Control Trial Study Not yet recruiting NCT05071638 Phase 3
48 Treatment of Classic Mid-trimester Preterm Premature Rupture of Membranes (PPROM) With Oligo/Anhydramnion Between 22/0-26/0 Week of Gestation by Means of Continuous Amnioinfusion: a Multicenter Prospectiv Randomized Trial Not yet recruiting NCT04696003 Phase 3
49 Management of Hyponatremia in Preterm Infants on Diuretics Terminated NCT00156572 Phase 3
50 Randomized Trial of Minimal Ventilator Support and Early Corticosteroid Therapy to Increase Survival Without Chronic Lung Disease in Extremely-Low-Birth-Weight Infants Terminated NCT00005777 Phase 3 Dexamethasone;Placebo

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM, cord blood-derived mesenchymal stem cells for bronchopulmonary dysplasia

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

Organs/tissues related to Bronchopulmonary Dysplasia:

MalaCards : Lung, Bone Marrow, Whole Blood, Brain, Heart, Fetal Lung, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Pulmonary Capillary Plexus Affected by disease
2 Lung Alveoli Alveolar Epithelial Type 1 Cells Affected by disease, potential therapeutic candidate
3 Lung Alveoli Alveolar Epithelial Type 2 Cells Affected by disease, potential therapeutic candidate

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 8331)
# Title Authors PMID Year
1
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. 53 62
18521627 2008
2
Clara cell secretory protein (CC16) as a peripheral blood biomarker of lung injury in ventilated preterm neonates. 53 62
18521628 2008
3
Gastrin-releasing peptide, immune responses, and lung disease. 53 62
19076373 2008
4
FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by Toll-like receptor activation. 53 62
17071719 2007
5
Selectin polymorphisms and perinatal morbidity in low-birthweight infants. 53 62
16982492 2006
6
Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. 53 62
16864707 2006
7
Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. 53 62
16856062 2006
8
The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. 53 62
15774846 2005
9
Erythrocyte Cu/Zn superoxide dismutase activity in preterm infants with and without bronchopulmonary dysplasia. 53 62
15767740 2005
10
Distribution of antioxidant enzymes in developing human lung, respiratory distress syndrome, and bronchopulmonary dysplasia. 53 62
15314090 2004
11
Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. 53 62
14711863 2004
12
Interleukin-10 inhibits proinflammatory chemokine release by neutrophils of the newborn without suppression of nuclear factor-kappa B. 53 62
12788980 2003
13
Soluble E-selectin, soluble L-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone. 53 62
12612222 2003
14
Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. 53 62
12475802 2002
15
Secretoglobins SCGB3A1 and SCGB3A2 define secretory cell subsets in mouse and human airways. 53 62
12406855 2002
16
High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia. 53 62
12016100 2002
17
Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. 53 62
11734454 2001
18
Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: relation to isolation of Ureaplasma urealyticum. 53 62
11478413 2001
19
Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. 53 62
11279743 2001
20
Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. 53 62
11015126 2000
21
An alternatively spliced surfactant protein B mRNA in normal human lung: disease implication. 53 62
10493923 1999
22
Hyperoxia induces thioredoxin and thioredoxin reductase gene expression in lungs of premature baboons with respiratory distress and bronchopulmonary dysplasia. 53 62
10424622 1999
23
Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. 53 62
9887057 1999
24
Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. 53 62
9605441 1998
25
L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. 53 62
9470000 1998
26
Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. 53 62
9372670 1997
27
Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. 53 62
9407566 1997
28
Airway lesions and superoxide dismutase (SOD) distribution in bronchopulmonary dysplasia (BPD). 53 62
9642974 1997
29
Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. 53 62
9369827 1997
30
Eosinophil cationic protein in tracheal aspirates of preterm infants with bronchopulmonary dysplasia. 53 62
9202617 1997
31
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia. 53 62
8853062 1996
32
Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. 53 62
8775225 1996
33
Use of the intramuscular relative-dose-response test to predict bronchopulmonary dysplasia in premature infants. 53 62
8604659 1996
34
Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. 53 62
7913723 1994
35
Proteinase-antiproteinase balance in tracheal aspirates from neonates. 53 62
7909297 1994
36
Pulmonary endocrine cells in infancy and childhood. 53 62
2014192 1991
37
Plasma retinol-binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia. 53 62
2108233 1990
38
Clinical characteristics and outcomes in neonates with perinatal acute respiratory distress syndrome in China: A national, multicentre, cross-sectional study. 62
36386029 2023
39
How lung injury and therapeutic oxygen could alter white matter development. 62
33687103 2022
40
Lung ultrasound assessment of pulmonary edema in neonates with chronic lung disease before and after diuretic therapy. 62
36174499 2022
41
Understanding the role of placental pathophysiology in the development of bronchopulmonary dysplasia. 62
36219136 2022
42
Maternal Ureaplasma exposure during pregnancy and the risk of preterm birth and BPD: a meta-analysis. 62
35277749 2022
43
Clinical Significance of Early Pulmonary Hypertension in Preterm Infants. 62
35934129 2022
44
Screening Echocardiography Identifies Risk Factors for Pulmonary Hypertension at Discharge in Premature Infants with Bronchopulmonary Dysplasia. 62
35488130 2022
45
Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial. 62
36345347 2022
46
Respiratory problems in preterm infants with pulmonary hemorrhage. 62
34384331 2022
47
Low flow nasal cannula requirement among preterm infants: predictors and description of clinical course. 62
36045221 2022
48
Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis. 62
36310242 2022
49
Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. 62
36008521 2022
50
Adverse perinatal outcomes in fetuses with severe late-onset fetal growth restriction. 62
34702116 2022

Variations for Bronchopulmonary Dysplasia

ClinVar genetic disease variations for Bronchopulmonary Dysplasia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ITGA3 NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro) SNV Uncertain Significance
1339481 GRCh37: 17:48153781-48153781
GRCh38: 17:50076417-50076417

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

Pathways related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 TXN TIMP1 SOD1 SELL RNASE3 IL1RN
2
Show member pathways
12.24 TIMP1 FLT1 FGF7 FGF10
3
Show member pathways
12.16 TIMP1 FLT1 FGF7 FGF10 CXCL8
4
Show member pathways
11.95 TIMP1 FLT1 FGF7 FGF10
5 10.93 TIMP1 FGF7 CXCL8
6 10.47 TIMP1 IL1RN CXCL8
7 10.46 TIMP1 FLT1 FGF7 FGF10 CXCL8

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.03 CXCL8 ELANE FGF10 FGF7 FLT1 IL1RN
2 extracellular region GO:0005576 9.68 TXN TIMP1 SOD1 SFTPB SCGB1A1 RNASE3

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lung development GO:0030324 9.85 RBP4 FGF7 FGF10
2 positive regulation of keratinocyte proliferation GO:0010838 9.78 FGF7 FGF10
3 induction of positive chemotaxis GO:0050930 9.73 FGF10 CXCL8
4 chemotaxis GO:0006935 9.73 RNASE3 FLT1 FGF10 CXCL8
5 response to organic substance GO:0010033 9.72 SCGB1A1 SOD1 TIMP1
6 positive regulation of keratinocyte migration GO:0051549 9.71 FGF7 FGF10
7 branching involved in salivary gland morphogenesis GO:0060445 9.54 FGF7 FGF10
8 secretion by lung epithelial cell involved in lung growth GO:0061033 9.46 FGF7 FGF10
9 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.26 FGF7 FGF10
10 female genitalia morphogenesis GO:0048807 8.92 RBP4 FGF10

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.32 SELL FGF7 FGF10 ELANE CXCL8
2 type 2 fibroblast growth factor receptor binding GO:0005111 9.26 FGF7 FGF10

Sources for Bronchopulmonary Dysplasia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....